Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 903

1.

Reduced Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long Term Follow-Up.

Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D.

Biol Blood Marrow Transplant. 2018 Aug 1. pii: S1083-8791(18)30427-0. doi: 10.1016/j.bbmt.2018.07.038. [Epub ahead of print]

PMID:
30077015
2.

ARID5B regulates metabolic programming in human adaptive NK cells.

Cichocki F, Wu CY, Zhang B, Felices M, Tesi B, Tuininga K, Dougherty P, Taras E, Hinderlie P, Blazar BR, Bryceson YT, Miller JS.

J Exp Med. 2018 Jul 30. pii: jem.20172168. doi: 10.1084/jem.20172168. [Epub ahead of print]

PMID:
30061358
3.

Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Jul 25. pii: clincanres.0945.2018. doi: 10.1158/1078-0432.CCR-18-0945. [Epub ahead of print]

PMID:
30045932
4.

Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.

Little MP, Wakeford R, Borrego D, French B, Zablotska LB, Adams MJ, Allodji R, de Vathaire F, Lee C, Brenner AV, Miller JS, Campbell D, Pearce MS, Doody MM, Holmberg E, Lundell M, Sadetzki S, Linet MS, Berrington de González A.

Lancet Haematol. 2018 Aug;5(8):e346-e358. doi: 10.1016/S2352-3026(18)30092-9. Epub 2018 Jul 17.

PMID:
30026010
5.

Current strategies exploiting NK-cell therapy to treat haematologic malignancies.

Johnson JK, Miller JS.

Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12387. [Epub ahead of print] Review.

PMID:
30009514
6.

HVAD: The ENDURANCE Supplemental Trial.

Milano CA, Rogers JG, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Mokadam NA, Mahr C, Miller JS, Markham DW, Jeevanandam V, Uriel N, Aaronson KD, Vassiliades TA, Pagani FD; ENDURANCE Investigators.

JACC Heart Fail. 2018 Jul 6. pii: S2213-1779(18)30389-5. doi: 10.1016/j.jchf.2018.05.012. [Epub ahead of print]

7.

Occupational radiation exposure and glaucoma and macular degeneration in the US radiologic technologists.

Little MP, Kitahara CM, Cahoon EK, Bernier MO, Velazquez-Kronen R, Doody MM, Borrego D, Miller JS, Alexander BH, Simon SL, Preston DL, Meyer C, Linet MS, Hamada N.

Sci Rep. 2018 Jul 11;8(1):10481. doi: 10.1038/s41598-018-28620-6.

8.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Don Yun H, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS.

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176. No abstract available.

9.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

10.

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.

Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, Hunt MA, Lou E, Miller JS.

J Immunother Cancer. 2018 Jun 19;6(1):58. doi: 10.1186/s40425-018-0357-3.

11.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

PMID:
29784636
12.

Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect.

Rashidi A, Ebadi M, Said B, Cao Q, Shanley R, Curtsinger J, Bejanyan N, Warlick ED, Green JS, Brunstein CG, Miller JS, Weisdorf DJ.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25141. [Epub ahead of print]

PMID:
29756385
13.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

PMID:
29735365
14.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR.

Blood Adv. 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances.2017014464.

15.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

16.

Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.

Burrack KS, Huggins MA, Taras E, Dougherty P, Henzler CM, Yang R, Alter S, Jeng EK, Wong HC, Felices M, Cichocki F, Miller JS, Hart GT, Johnson AJ, Jameson SC, Hamilton SE.

Immunity. 2018 Apr 17;48(4):760-772.e4. doi: 10.1016/j.immuni.2018.03.012. Epub 2018 Apr 3.

PMID:
29625893
17.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Mar 27. pii: S1083-8791(18)30132-0. doi: 10.1016/j.bbmt.2018.03.019. [Epub ahead of print]

PMID:
29597002
18.

Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, McKenna DH Jr.

Transfusion. 2018 Jun;58(6):1458-1467. doi: 10.1111/trf.14564. Epub 2018 Mar 12.

PMID:
29532488
19.

Organic-based magnon spintronics.

Liu H, Zhang C, Malissa H, Groesbeck M, Kavand M, McLaughlin R, Jamali S, Hao J, Sun D, Davidson RA, Wojcik L, Miller JS, Boehme C, Vardeny ZV.

Nat Mater. 2018 Apr;17(4):308-312. doi: 10.1038/s41563-018-0035-3. Epub 2018 Mar 12.

PMID:
29531369
20.

Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2018 Aug;53(8):1069-1071. doi: 10.1038/s41409-018-0127-3. Epub 2018 Mar 7. No abstract available.

PMID:
29515246
21.

Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.

de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162. doi: 10.1016/j.bbmt.2018.02.023. Epub 2018 Mar 2.

PMID:
29505821
22.

Quality of care in integrated community case management services in Bugoye, Uganda: a retrospective observational study.

Miller JS, English L, Matte M, Mbusa R, Ntaro M, Bwambale S, Kenney J, Siedner MJ, Reyes R, Lee PT, Mulogo E, Stone GS.

Malar J. 2018 Feb 27;17(1):99. doi: 10.1186/s12936-018-2241-5.

23.

Effect of Progressive Calisthenic Push-up Training on Muscle Strength and Thickness.

Kotarsky CJ, Christensen BK, Miller JS, Hackney KJ.

J Strength Cond Res. 2018 Mar;32(3):651-659. doi: 10.1519/JSC.0000000000002345.

PMID:
29466268
24.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

PMID:
29463563
25.

Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.

Liu B, Jones M, Kong L, Noel T, Jeng EK, Shi S, England CG, Alter S, Miller JS, Cai W, Rhode PR, Wong HC.

Cytokine. 2018 Jul;107:105-112. doi: 10.1016/j.cyto.2017.12.003. Epub 2018 Feb 13.

PMID:
29452720
26.

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikström K, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ.

Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. doi: 10.1158/1078-0432.CCR-17-3196. Epub 2018 Feb 14.

PMID:
29444931
27.

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.

Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, Geller MA, Tolar J, Blazar BR, Miller JS.

JCI Insight. 2018 Feb 8;3(3). pii: 96219. doi: 10.1172/jci.insight.96219. [Epub ahead of print]

28.

NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).

de Witte MA, Kuball J, Miller JS.

Curr Stem Cell Rep. 2017 Dec;3(4):301-311. doi: 10.1007/s40778-017-0106-4. Epub 2017 Oct 16.

PMID:
29399441
29.

Rate and Risk Factors Associated with Autism Spectrum Disorder in Congenital Diaphragmatic Hernia.

Danzer E, Hoffman C, D'Agostino JA, Miller JS, Waqar LN, Gerdes M, Bernbaum JC, Rosenthal H, Rintoul NE, Herkert LM, Peranteau WH, Flake AW, Adzick NS, Hedrick HL.

J Autism Dev Disord. 2018 Jun;48(6):2112-2121. doi: 10.1007/s10803-018-3472-6.

PMID:
29383650
30.

Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.

Cooley S, Parham P, Miller JS.

Blood. 2018 Mar 8;131(10):1053-1062. doi: 10.1182/blood-2017-08-752170. Epub 2018 Jan 22. Review.

PMID:
29358179
31.

Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.

Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA.

Front Immunol. 2018 Jan 5;8:1825. doi: 10.3389/fimmu.2017.01825. eCollection 2017. Review.

32.

Negative Valence in Autism Spectrum Disorder: The Relationship Between Amygdala Activity, Selective Attention, and Co-occurring Anxiety.

Herrington JD, Maddox BB, McVey AJ, Franklin ME, Yerys BE, Miller JS, Schultz RT.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Sep;2(6):510-517. doi: 10.1016/j.bpsc.2017.03.009. Epub 2017 Mar 22.

PMID:
29348040
33.

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO.

Biol Blood Marrow Transplant. 2018 May;24(5):895-908. doi: 10.1016/j.bbmt.2018.01.008. Epub 2018 Jan 12. Review.

PMID:
29339270
34.

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS.

Cancer Immunol Immunother. 2018 Mar;67(3):483-494. doi: 10.1007/s00262-017-2100-1. Epub 2017 Dec 7.

35.

Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.

Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA.

JCI Insight. 2017 Dec 7;2(23). pii: 95128. doi: 10.1172/jci.insight.95128. [Epub ahead of print]

36.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
37.

Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.

Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, Verneris MR.

Biol Blood Marrow Transplant. 2018 Mar;24(3):618-622. doi: 10.1016/j.bbmt.2017.11.022. Epub 2017 Nov 29.

PMID:
29197679
38.

Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 Response.

Bergerson RJ, Williams R, Wang H, Shanley R, Colbenson G, Kerber A, Cooley S, Curtsinger J, Felices M, Miller JS, Verneris MR.

Blood Adv. 2016 Dec 27;1(3):208-218. doi: 10.1182/bloodadvances.2016000158. Epub 2016 Oct 30.

39.

ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.

Ellis-Connell AL, Balgeman AJ, Zarbock KR, Barry G, Weiler A, Egan JO, Jeng EK, Friedrich T, Miller JS, Haase AT, Schacker TW, Wong HC, Rakasz E, O'Connor SL.

J Virol. 2018 Jan 17;92(3). pii: e01748-17. doi: 10.1128/JVI.01748-17. Print 2018 Feb 1.

40.

Critical region within 22q11.2 linked to higher rate of autism spectrum disorder.

Clements CC, Wenger TL, Zoltowski AR, Bertollo JR, Miller JS, de Marchena AB, Mitteer LM, Carey JC, Yerys BE, Zackai EH, Emanuel BS, McDonald-McGinn DM, Schultz RT.

Mol Autism. 2017 Oct 27;8:58. doi: 10.1186/s13229-017-0171-7. eCollection 2017.

41.

Host conservatism, geography, and elevation in the evolution of a Neotropical moth radiation.

Jahner JP, Forister ML, Parchman TL, Smilanich AM, Miller JS, Wilson JS, Walla TR, Tepe EJ, Richards LA, Quijano-Abril MA, Glassmire AE, Dyer LA.

Evolution. 2017 Dec;71(12):2885-2900. doi: 10.1111/evo.13377. Epub 2017 Nov 22.

PMID:
29055110
42.

Structures of a Complex Hydrazinium Lead Iodide, (N2 H5 )15 Pb3 I21 , Possessing [Pb2 I9 ]5- , [PbI6 ]4- , and I- Ions and α- and β-(N2 H5 )PbI3.

Campbell EV, Dick B, Rheingold AL, Zhang C, Liu X, Vardeny ZV, Miller JS.

Chemistry. 2018 Jan 2;24(1):222-229. doi: 10.1002/chem.201704356. Epub 2017 Dec 4.

PMID:
29029371
43.

Clinical Outcomes of Different Tempos of Music During Exercise in Cardiac Rehabilitation Patients.

Miller JS, Terbizan DJ.

Int J Exerc Sci. 2017 Sep 1;10(5):681-689. eCollection 2017.

44.

Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, Betz K, Brown M, Schell JB, Zeleski K, Yu A, Kirby I, Cooley S, Miller JS, Blazar BR, Casson D, Bland-Ward P, Kean LS.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan3085. doi: 10.1126/scitranslmed.aan3085.

PMID:
28931653
45.

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

Davis ZB, Vallera DA, Miller JS, Felices M.

Semin Immunol. 2017 Jun;31:64-75. doi: 10.1016/j.smim.2017.07.011. Epub 2017 Sep 5. Review.

PMID:
28882429
46.

Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study.

Steiner AJ, Recacho J, Vanle B, Dang J, Wright SM, Miller JS, Kauzor K, Reid M, Bashmi LE, Mirocha J, Danovitch I, IsHak WW.

J Clin Psychiatry. 2017 Jul;78(7):897-903. doi: 10.4088/JCP.16m11335.

PMID:
28858443
47.

Lagging skills contribute to challenging behaviors in children with autism spectrum disorder without intellectual disability.

Maddox BB, Cleary P, Kuschner ES, Miller JS, Armour AC, Guy L, Kenworthy L, Schultz RT, Yerys BE.

Autism. 2017 Aug 1:1362361317712651. doi: 10.1177/1362361317712651. [Epub ahead of print]

PMID:
28844152
48.

Isolation of the New Antiplasmodial Butanolide, Malleastrumolide A, from Malleastrum sp. (Meliaceae) from Madagascar.

Du Y, Abedi AK, Valenciano AL, Fernández-Murga ML, Cassera MB, Rasamison VE, Applequist WL, Miller JS, Kingston DGI.

Chem Biodivers. 2017 Dec;14(12). doi: 10.1002/cbdv.201700331. Epub 2017 Dec 15.

PMID:
28817228
49.

Increase in the Magnetic Ordering Temperature (Tc) as a Function of the Applied Pressure for A2Mn[Mn(CN)6] (A = K, Rb, Cs) Prussian Blue Analogues.

Sugimoto M, Yamashita S, Akutsu H, Nakazawa Y, DaSilva JG, Kareis CM, Miller JS.

Inorg Chem. 2017 Sep 5;56(17):10452-10457. doi: 10.1021/acs.inorgchem.7b01402. Epub 2017 Aug 15.

PMID:
28809550
50.

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.

Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS.

Cancer Res. 2017 Oct 15;77(20):5664-5675. doi: 10.1158/0008-5472.CAN-17-0799. Epub 2017 Aug 8.

PMID:
28790065

Supplemental Content

Loading ...
Support Center